Free Trial
NASDAQ:BCAB

BioAtla Q3 2026 Earnings Results & Report

BioAtla logo
$1.99 +0.43 (+27.56%)
As of 02:30 PM Eastern

BioAtla beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$4.74 versus the -$7.00 consensus estimate, while revenue of $250 thousand fell short of the $5.59 million estimate by $5.34 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

BioAtla EPS Results

Actual EPS
-$4.74
Consensus EPS
-$7.00
Beat/Miss
Beat by +$2.26
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

BioAtla Revenue Results

Actual Revenue
$250 thousand
Expected Revenue
$5.59 million
Beat/Miss
Missed by -$5.34 million
YoY Revenue Growth
N/A

Earnings Documents

BioAtla Q3 2026 Earnings FAQ

BioAtla (NASDAQ:BCAB) reported earnings of -$4.74 per share for Q3 2026, beating the consensus estimate of -$7.00. The report was announced on Monday, November 16, 2026.

BioAtla reported revenue of $250 thousand for Q3 2026, against a consensus estimate of $5.59 million.

BioAtla Earnings Headlines

BioAtla (BCAB) Projected to Post Quarterly Earnings on Thursday
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
BioAtla Announces Share Consolidation
See More BioAtla Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAtla? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAtla and other key companies, straight to your email.

About BioAtla

BioAtla (NASDAQ:BCAB) was a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company used its Conditionally Active Biologics (CAB) platform to design antibody-based medicines intended to become active primarily within the tumor microenvironment, with the goal of improving treatment effectiveness while limiting effects on healthy tissue.

BioAtla’s investigational pipeline included antibody-drug conjugates and immune-modulating therapies. Its lead programs included mecbotamab vedotin, an antibody-drug conjugate designed to target AXL, and ozuriftamab vedotin, an investigational therapy directed at ROR2. The company also evaluated other CAB-based candidates for potential use in solid tumors and hematologic malignancies.

BioAtla was founded in 2007 and was headquartered in San Diego, California. Its programs were developed for potential treatment of cancers in the United States and international markets through clinical research and collaborations. The company later announced a strategic review and substantial reductions to its operations, and its publicly traded activities were subsequently wound down.

View BioAtla Profile